menu
    • menu

    Company profile for Napo EU

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Napo EU S.p.A. is focused on developing crofelemer for the European market. Napo EU is the Italian subsidiary of Napo Pharmaceuticals, a commercial-stage pharmaceutical company based in San Francisco, California, that markets crofelemer in the US and is a wholly owned subsidiary of Jaguar Health. Napo Pharmaceuticals’ focus is on developing and commercializing novel, plant-based, sustainably derived prescription medicines fo...
    Napo EU S.p.A. is focused on developing crofelemer for the European market. Napo EU is the Italian subsidiary of Napo Pharmaceuticals, a commercial-stage pharmaceutical company based in San Francisco, California, that markets crofelemer in the US and is a wholly owned subsidiary of Jaguar Health. Napo Pharmaceuticals’ focus is on developing and commercializing novel, plant-based, sustainably derived prescription medicines for people with life-altering gastrointestinal (GI) distress—specifically chronic GI malabsorption or debilitating volume and frequency of GI output.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Napo EUItaly Flag
    Country
    Country
    Italy
    Address
    Address
    Corso Giacomo Matteotti Milano (MI), CAP 20121
    Telephone
    Telephone
    (415) 963-9938
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://napopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/napopharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Health Strengthens Global IP With New Crofelemer Patent
    Jaguar Health Strengthens Global IP With New Crofelemer Patent

    24 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-24/jaguar-health-secures-new-patent-for-crofelemer-in-short-bowel-syndrome-strengthening-global-ip-pos

    PHARMIWEB
    24 Nov 2025
    Share Share
    Jaguar Health Provides Recap of November 8, 2025 Presentation
    Jaguar Health Provides Recap of November 8, 2025 Presentation

    13 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-13/jaguar-health-provides-recap-of-november-8-2025-presentation-on-groundbreaking-results-of-proof-of

    PHARMIWEB
    13 Nov 2025
    Share Share
    Jaguar Health Unveils Crofelemer for Pediatric Intestinal Failure
    Jaguar Health Unveils Crofelemer for Pediatric Intestinal Failure

    06 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-06/reminder-initial-groundbreaking-results-of-proof-of-concept-study-of-jaguar-healths-crofelemer-for

    PHARMIWEB
    06 Nov 2025
    Share Share
    Jaguar Health Meets FDA To Advance Crofelemer Trial
    Jaguar Health Meets FDA To Advance Crofelemer Trial

    06 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-06/jaguar-health-completes-meeting-with-fda-for-advice-on-development-pathways-to-advance-ongoing-crofe

    PHARMIWEB
    06 Oct 2025
    Share Share
    Jaguar Health Seeks FDA Orphan Drug Designation for Crofelemer
    Jaguar Health Seeks FDA Orphan Drug Designation for Crofelemer

    24 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-24/jaguar-health-submits-orphan-drug-designation-application-to-fda-for-crofelemer-for-cancer-therapy-r

    PHARMAWEB
    24 Sep 2025
    Share Share
    Jaguar Health Launches FDA-Approved Gelclair In The U.S.
    Jaguar Health Launches FDA-Approved Gelclair In The U.S.

    16 Oct 2024

    // ACCESSWIRE

    https://www.accesswire.com/932088/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-us

    ACCESSWIRE
    16 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search